These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37070961)

  • 1. Ferrocenoyl-substituted quinolinone and coumarin as organometallic inhibitors of SARS-CoV-2 3CLpro main protease.
    Graf D; Farn N; Klopf J; Hojjati M; Schatzschneider U
    Metallomics; 2023 May; 15(5):. PubMed ID: 37070961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.
    Kumar V; Roy K
    SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
    Gurard-Levin ZA; Liu C; Jekle A; Jaisinghani R; Ren S; Vandyck K; Jochmans D; Leyssen P; Neyts J; Blatt LM; Beigelman L; Symons JA; Raboisson P; Scholle MD; Deval J
    Antiviral Res; 2020 Oct; 182():104924. PubMed ID: 32896566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
    Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
    Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors.
    Jo S; Signorile L; Kim S; Kim MS; Huertas O; Insa R; Reig N; Shin DH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening.
    Sanachai K; Somboon T; Wilasluck P; Deetanya P; Wolschann P; Langer T; Lee VS; Wangkanont K; Rungrotmongkol T; Hannongbua S
    PLoS One; 2022; 17(6):e0269563. PubMed ID: 35771802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.
    Liu C; Boland S; Scholle MD; Bardiot D; Marchand A; Chaltin P; Blatt LM; Beigelman L; Symons JA; Raboisson P; Gurard-Levin ZA; Vandyck K; Deval J
    Antiviral Res; 2021 Mar; 187():105020. PubMed ID: 33515606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors.
    Bao HL; Tu G; Yue Q; Liu P; Zheng HL; Yao XJ
    Chem Biol Drug Des; 2023 Oct; 102(4):857-869. PubMed ID: 37563791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a red-shifted fluorescence-based assay for SARS-coronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata.
    Hamill P; Hudson D; Kao RY; Chow P; Raj M; Xu H; Richer MJ; Jean F
    Biol Chem; 2006 Aug; 387(8):1063-74. PubMed ID: 16895476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QSAR modeling and pharmacoinformatics of SARS coronavirus 3C-like protease inhibitors.
    Ishola AA; Adedirin O; Joshi T; Chandra S
    Comput Biol Med; 2021 Jul; 134():104483. PubMed ID: 34020129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring 2-methyl-substituted vitamin K
    Koharazawa R; Hayakawa M; Takeda K; Miyazaki K; Tode C; Hirota Y; Suhara Y
    Bioorg Med Chem Lett; 2024 Mar; 100():129642. PubMed ID: 38310976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Chalcone-Based Hybrid Structures as High Affinity and Site-Specific Inhibitors against SARS-CoV-2: A Comprehensive Structural Analysis Based on Various Host-Based and Viral Targets.
    Valipour M; Di Giacomo S; Di Sotto A; Irannejad H
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidation of the inhibitory activity of plant-derived SARS-CoV inhibitors and their potential as SARS-CoV-2 inhibitors.
    Bello M; Hasan MK
    J Biomol Struct Dyn; 2022; 40(20):9992-10004. PubMed ID: 34121618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.
    Du A; Zheng R; Disoma C; Li S; Chen Z; Li S; Liu P; Zhou Y; Shen Y; Liu S; Zhang Y; Dong Z; Yang Q; Alsaadawe M; Razzaq A; Peng Y; Chen X; Hu L; Peng J; Zhang Q; Jiang T; Mo L; Li S; Xia Z
    Int J Biol Macromol; 2021 Apr; 176():1-12. PubMed ID: 33548314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus.
    Qiao Z; Wei N; Jin L; Zhang H; Luo J; Zhang Y; Wang K
    Bioorg Chem; 2021 Dec; 117():105455. PubMed ID: 34740055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of Dihydrobenzofuro[3,2-b]chromenes as Potential 3CLpro Inhibitors of SARS-CoV-2: A Molecular Docking and Molecular Dynamics Study.
    Gorai S; Junghare V; Kundu K; Gharui S; Kumar M; Patro BS; Nayak SK; Hazra S; Mula S
    ChemMedChem; 2022 Apr; 17(8):e202100782. PubMed ID: 35112482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor
    Jochmans D; Liu C; Donckers K; Stoycheva A; Boland S; Stevens SK; De Vita C; Vanmechelen B; Maes P; Trüeb B; Ebert N; Thiel V; De Jonghe S; Vangeel L; Bardiot D; Jekle A; Blatt LM; Beigelman L; Symons JA; Raboisson P; Chaltin P; Marchand A; Neyts J; Deval J; Vandyck K
    mBio; 2023 Feb; 14(1):e0281522. PubMed ID: 36625640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.